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Endocarditis is a potentially life-threatening clinical
disease with various manifestations such as fever of
unknown origin, embolic phenomena, persistent bac-
teremia, or complications with cerebral vascular acci-
dents (cerebral embolism). It is challenging to reach 
a definitive diagnosis of infective endocarditis (IE).
Culture-negative endocarditis sometimes delays the
proper diagnosis. Modified Duke’s criteria are useful
for clinical diagnosis, but a positive blood culture still
provides the cornerstone for effective antimicrobial
treatment.1 The bacterial etiology of endocarditis con-
sists of both Gram-positive cocci and negative bacilli.
Among them, Staphylococcus aureus is one of the lead-
ing pathogens, especially among intravenous drug users.
S. aureus is a common pathogen in hospital-acquired
infections, including respiratory tract infections, sur-
gical wounds, and blood stream infections. Based on
antimicrobial susceptibility profiles, S. aureus is tradi-
tionally classified into methicillin-resistant S. aureus
(MRSA) or methicillin-sensitive S. aureus (MSSA). The
pathogen is further referred to as community-associated
(CA) or health care-associated (HA) based on the pos-
sible origins of acquiring the microorganism. At the
early stage of the antibiotics era, Alexander Fleming
discovered penicillin, which was used to treat S. aureus
infections. In approximately 1 year, penicillin-resistant
S. aureus emerged. Methicillin was introduced to the
market in 1959 for treating S. aureus infections, but
MRSA was observed shortly after in the early 1960s.
Although vancomycin has been approved for use since
1958, the drug is not generally used because of its side
effects.2,3 During the antibiotics era, MRSA emerged
and prevailed, and HA-MRSA became the predominant
strain in most hospitals, but community infections were
still MSSA. In the 1990s, the first CA-MRSA was re-
ported in the United States (US),3 and the incidence
of CA-MRSA has increased in recent years, not only
within the US, but also all over the world.
CA-MRSA is distinct from HA-MRSA clinically,
bacteriologically, epidemiologically, and genetically.
CA-MRSA is primarily associated with healthy in-
dividual skin and soft tissue infections.3,4 However,
invasive diseases, including bacteremia, endocarditis,
osteomyelitis, and hemorrhagic necrotizing pneumo-
nia, have been reported.4,5 It is uncommon to find
CA-MRSA-related endocarditis among intravenous
drug users. The antibiograms of CA-MRSA are easily
distinguished from those of HA-MRSA, with bacteria
sensitive to clindamycin, trimethoprim/sulfamethox-
azole, and rifampin. To genetically differentiate CA-
MRSA and HA-MRSA, pulse field gel electrophoresis
(PFGE) was the typing method of choice in the late
1990s. Recently, multilocus sequence typing, staphy-
lococcal chromosomal cassette mec (SCCmec) typing,
and staphylococcus protein A (spa) typing have also
been used to characterize S. aureus isolates.4 Most of
the CA-MRSAs belong to the type IV SCCmec, while
HA-MRSAs belong to types I to III. Although the
PFGE technique has been highly successful in iden-
tifying epidemiologically related isolates as well as si-
multaneously differentiating among unrelated isolates,
there has been inconsistency among laboratories in
the interpretation of the bending patterns and nam-
ing. The potent Panton-Valentine leukocidin (PVL)
toxin gene is frequently associated with CA-MRSA
and is detected in fewer than 5% of hospital strains.
This toxin kills leukocytes by forming pores in the cell
membrane and is associated with skin abscesses and
rapidly progressive necrotizing pneumonia in both
MRSA and MSSA.3
Before 2007, reports of cases of CA-MRSA IE
were limited to industrialized and developed regions,
EDITORIAL COMMENT
Community-acquired Methicillin Resistant
Staphylococcus aureus and Endocarditis: 
An Emerging Pathogen?
Yu-Jiun Chan*
Division of Clinical Virology, Department of Pathology and Laboratory Medicine, 
Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
© 2010 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
*Correspondence to: Dr Yu-Jiun Chan, Division of Clinical Virology, Department of Pathology and Laboratory
Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C.
E-mail: yjchan@vghtpe.gov.tw ● Received: October 29, 2009 ● Accepted: December 28, 2009
with most originating in the US, and a few case reports
in developing countries thereafter.5,6 A comprehensive
literature survey by Millar et al identified 23 cases of
CA-MRSA IE, and the authors stressed the character-
istics of a documented history of some form of skin
lesion, including intravenous drug abuse and native
valve involvement with predominately the tricuspid
valve.5 In the December 2009 issue of the Journal of
the Chinese Medical Association, Chao et al7 reported
37 episodes of community-acquired endocarditis. They
retrospectively reviewed the patients’ clinical manifes-
tations and bacteriological characteristics. The most
common clinical symptoms were fever and embolic
phenomena, with predominately MSSA (76%) infec-
tions. Aside from the common bacterial species, the
authors reported 4 cases of CA-MRSA IE among
intravenous drug users. They had previously reported
the first HIV positive patient with CA-MRSA IE in
Taiwan.8 Further molecular analyses, including PFGE
and polymerase chain reaction for marker and viru-
lent genes (such as PVL, Hlg and mec) confirmed the
heterogeneous origin. Interestingly, the prototypic CA-
MRSA, USA300, which contains the type IV SCCmec
that enhances its antimicrobial resistance, was not found
in this study. Instead, there was a predominance of
type III SCCmec, which principally resides in the HA-
MRSA, indicating a mixing between CA-MRSA and
HA-MRSA or outward spreading of the HA-MRSA
to the community. It would be more convincing for
the authors to combine the multilocus sequence typ-
ing and SCCmec techniques to confirm the origins of
the study isolates. Another toxic gene, PVL, which is
associated with abscess formation, was detected in half
(2/4) of the CA-MRSA cases. It is interesting that the
authors reported combined SCCmec type III and PVL
positive isolates among IE patients, again indicating a
possible mixing of hospital and community origins.
Previous reports have indicated that CA-MRSA is in-
vading the hospitals. It is very likely that the vice versa
will occur.3
The prototypic CA-MRSA type, USA300, was first
reported in 2003 by McDougal et al as 1 of the 8 ini-
tial MRSA “USA” strain types.9 The “USA300” strain
type carries the genes encoding PVL and SCCmec
type IV. S. aureus isolates of this linage show closely
related PFGE banding patterns, indicating a family of
isolates with related PFGE patterns. Previous findings
of CA-MRSA reported in Taiwan show a predomi-
nant SCCmec type IV and a novel VT type.10
Treating bacterial endocarditis requires a compre-
hensive evaluation of the patient’s clinical condition
and the choice of the best modality, including effec-
tive and prolonged antibiotics administration, surgical
intervention, or both.5 Oxacillin-based treatment for
MSSA endocarditis has been reported to be superior
to vancomycin-based treatment in terms of cure rates
and preventing relapse.11,12 For the treatment of en-
docarditis caused by MRSA, few choices are left. Tra-
ditionally, glycopeptides such as vancomycin are the
drugs of choice.5 However, treatment with vancomy-
cin is significantly associated with relapse.12 Recently
introduced antimicrobial agents for drug resistant 
S. aureus infections such as linezolid, daptomycin, or
tigecycline, might play a role.12 Linezolid is a syn-
thetic bacteriostatic agent and its long-term use is
prohibited due to serious adverse drug effects such 
as bone marrow suppression, optic neuropathy and
lactic acidosis. Daptomycin is another new class of
semi-synthetic cyclic lipopeptide, which exerts its bac-
tericidal effects through calcium-dependent insertion
of the drug into bacterial cell membranes and causing
potassium leakage. Several double-blind controlled
studies have demonstrated the superiority of dapto-
mycin over vancomycin on right-side MRSA endo-
carditis.11 Although there were insufficient data for
left-side endocarditis treatment, preliminary results
were promising. However, daptomycin is not indi-
cated for the treatment of pulmonary infections due
to the inhibitory effect of surfactant. It would be
problematic to treat endocarditis complicated with
pulmonary septic emboli with daptomycin alone. Sur-
gical intervention with valvular replacement is another
arm of treatment, especially when the patient presents
with persistent bacteremia, embolic lesions over vital
organs, or valvular damage.
In conclusion, the emergence of CA-MRSA IE
among intravenous drug users is a cause for concern.
Considering the limited effective antimicrobial agents
against CA-MRSA IE, it is imperative to cautiously
and properly use antibiotics. At the same time, com-
bining close surveillance of the CA-MRSA epidemio-
logical trend and appropriate infectious control tactics,
it might be possible to halt the spread of CA-MRSA.
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